Israel-based generics giant Teva Pharmaceutical Industries (NYSE: TEVA) posted first-quarter 2016 financials, indicating that it is itself facing competition for its branded copy medicines.
However, the results beat analysts’ expectations and the firm’s share rose 3% to $51.76 in pre-market trading.
On an adjusted basis, Teva's net earnings fell 5.1% to $1.11 billion, while earnings per share fell 11.8% to $1.20. That was $0.03 a share higher than the Wall Street analysts' expectations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze